EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Other Sources: 10

Soy isoflavones

Also called: isoflavones, genistein, daidzein, glycitein, soybean isoflavones

Isoflavones are compounds in soybeans (Glycine max), including genistein, daidzein and glycitein, that NCCIH describes as similar in structure to the hormone estrogen. Supplements supply isoflavones extracted from soy; some studied products were chemically synthesized.

Category
Other
Forms
Isolated soy isoflavones (extracts), as aglycones or beta-glycosides; some studied isoflavones were chemically synthesized
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. A 2012 meta-analysis included 19 double-blind RCTs of extracted or synthesized soy isoflavones versus placebo for hot flashes and pooled 17 of them. [4]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied2 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Soy isoflavones does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Soy isoflavones, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Hot flashes in peri- and postmenopausal womenBA 2012 meta-analysis of double-blind RCTs found soy isoflavones (median 54 mg/day, 6 weeks to 12 months) reduced hot-flash frequency by 20.6% and severity by 26.2% versus placebo, with high heterogeneity. [4]
Bone mineral density in postmenopausal womenBA 2024 meta-analysis of 63 RCTs (4,754 isoflavone and 4,272 placebo participants) found BMD gains at lumbar spine, femoral neck and distal radius, mainly with 12 months or more and at least 50 mg/day genistein. [6]
Total and LDL cholesterol in menopausal women (isoflavone extract alone)XA meta-analysis of randomized placebo-controlled trials (10 and 9 trials) found about 70 mg/day extracted isoflavones alone for 1–3 months did not improve total or LDL cholesterol in normocholesterolemic menopausal women. [5]
Breast cancer riskCNCCIH: observational studies link higher soy intake in Asian and Asian-American women to lower breast cancer risk, but soy products in supplement form have not been shown to reduce breast cancer risk. [1]

Main constituents: Isoflavones genistein, daidzein and glycitein [2]; Aglycones (genistein, daidzein) and their beta-glycosides; glycitin is hydrolyzed to glycitein in the body [8]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Hot-flash trials: median 54 mg/day soy isoflavones (aglycone equivalents) for 6 weeks to 12 months. [4]
  • Cholesterol trials: an average of 70 mg/day (27–132 mg, as aglycones) of extracted isoflavones for 1–3 months. [5]
  • EFSA's assessment covered human intervention studies using 30–900 mg/day; uterine data extended to 150 mg/day of soy isoflavones. [3]

Upper limits

  • EFSA (2015) concluded it was not possible to derive a single health-based guidance value for the different isoflavone preparations in post-menopausal women. [3]
Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    NCCIH: soy use during pregnancy may be unsafe in amounts greater than those commonly found in foods …

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    5 listed

    Tamoxifen; Aromatase inhibitors; Simvastatin; Levothyroxine; Monoamine oxidase inhibitors (MAOIs)

    Details and sources
  • Cancer evaluations (IARC, NTP)
    1 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    3 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • EFSA (2015): no effect on endometrial thickness or uterine histopathology up to 30 months of 150 mg/day soy isoflavones; after 60 months some non-malignant histopathological changes were reported. [3]
  • EFSA's conclusions apply only to post-menopausal women without a current diagnosis or history of estrogen-dependent breast or uterine cancer; data for peri-menopausal women were limited. [3]
  • EFSA: human data did not support an increased breast cancer risk or effects on mammographic density or Ki-67; thyroid hormone levels were not changed by isoflavone food supplements. [3]
  • Possible side effects include bloating, constipation, diarrhea and nausea; concentrated isoflavone extracts were used safely for up to 6 months in research studies. [1]
  • Some people are allergic to soy; US labels must disclose soy in packaged foods and supplements. [1]
  • A meta-analysis of 23 randomized placebo-controlled trials (2,167 subjects) found no significant overall change in endometrial thickness with oral isoflavone supplementation. [7]
Interactions

Interactions

Soy isoflavones
From the table below 5 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Soy isoflavones
WithWhat happens
TamoxifenMSK: animal studies suggest genistein may antagonize tamoxifen effects on estrogen-dependent breast cancer (MCF-7); clinical relevance has yet to be determined. [2]
Aromatase inhibitorsMSK states soy-based supplements may affect treatment efficacy; genistein increased aromatase expression and activity in vitro. [2]
SimvastatinMSK: repeated administration of soy isoflavones decreased the systemic bioavailability of simvastatin in healthy volunteers. [2]
LevothyroxineMSK: a few case reports suggest soy products may interfere with levothyroxine absorption; a crossover study found no such effect. [2]
Monoamine oxidase inhibitors (MAOIs)NCCIH: soy products high in tyramine, such as tofu and soy sauce, can interact with MAOIs and have been linked to dangerously high blood pressure. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • An analysis of 33 phytoestrogen supplements and extracts found considerable differences between measured isoflavone content and manufacturers' claims. [8]
Regulation

Regulatory status

  • EU: EFSA assessed food supplements containing isolated isoflavones for peri- and post-menopausal women in 2015 (EFSA Journal 2015;13(10):4246). [3]
  • US: FDA's published NDI notification list has 3 entries naming soy isoflavones or a soybean isoflavone ingredient (earliest NDI 759 submitted 2012-04-26; most recent NDI 1283 submitted 2023-02-24). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [9]
  • US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [10]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Genistein, daidzein and glycitein Flavonoids (isoflavones) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 3 entries naming soy isoflavones or a soybean isoflavone ingredient (earliest NDI 759 submitted 2012-04-26; most recent NDI 1283 submitted 2023-02-24). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC classification of soy isoflavones, genistein or daidzein was found (IARC Monographs list of classifications checked 2026-10-29). [P3]
  • NTP TR-545 (genistein in feed at 5, 100 or 500 ppm, Sprague-Dawley rats, 2-year study): no evidence of carcinogenic activity in males; some evidence in females with continuous exposure from conception (mammary gland adenoma or adenocarcinoma combined, and pituitary gland neoplasms). [P5]
  • In TR-545, females whose exposure stopped at 20 weeks or at weaning showed equivocal evidence (pituitary neoplasms, or mammary adenoma or adenocarcinoma combined, respectively). [P5]
  • The NTP technical reports list also includes a multigenerational reproductive toxicology study of genistein in Sprague-Dawley rats (TR-539); no NTP report on soy isoflavone mixtures or daidzein was listed. [P4]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Tamoxifen: MSK: animal studies suggest genistein may antagonize tamoxifen effects on estrogen-dependent breast cancer (MCF-7); clinical relevance has yet to be determined. [P1]
  • Aromatase inhibitors: MSK states soy-based supplements may affect treatment efficacy; genistein increased aromatase expression and activity in vitro. [P1]
  • Simvastatin: MSK: repeated administration of soy isoflavones decreased the systemic bioavailability of simvastatin in healthy volunteers. [P1]
  • Levothyroxine: MSK: a few case reports suggest soy products may interfere with levothyroxine absorption; a crossover study found no such effect. [P1]
  • Monoamine oxidase inhibitors (MAOIs): NCCIH: soy products high in tyramine, such as tofu and soy sauce, can interact with MAOIs and have been linked to dangerously high blood pressure. [P8]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • Setchell et al. (2001) analyzed 33 phytoestrogen supplements and extracts and found considerable differences in isoflavone content from that claimed by manufacturers. [P6]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P7]
  • Isoflavone content and profile (genistein, daidzein, glycitein and their glycosides) — Measured isoflavone content differed considerably from label claims in 33 supplements and extracts; isoflavones differ in pharmacokinetics, so they cannot be assumed comparable. [P6]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • In 19 healthy women given single doses of pure isoflavones, mean tmax was 5.2 h (genistein) and 6.6 h (daidzein) for aglycones and 9.3 h and 9.0 h for their beta-glycosides. [P6]
  • Genistein's systemic bioavailability (mean AUC 4.54 µg/(mL x h)) was greater than daidzein's (2.94); bioavailability was greater when taken as beta-glycosides than as aglycones. [P6]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • NCCIH: soy use during pregnancy may be unsafe in amounts greater than those commonly found in foods; little is known about safety during breastfeeding at such amounts. [P8]

Sources for this profile

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Soy (Last Updated July 24, 2026), 2026-07-24. mskcc.org
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  4. National Toxicology Program (NIEHS). Technical Reports list (TR-001 to TR-606; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  5. National Toxicology Program. TR-545: Toxicology and Carcinogenesis Study of Genistein (CASRN 446-72-0) in Sprague-Dawley Rats (Feed Study) (December 2007), 2007-12. ntp.niehs.nih.gov
  6. Setchell KD, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131(4 Suppl):1362S-75S (PMID 11285356), 2001-04. pubmed.ncbi.nlm.nih.gov
  7. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  8. NCCIH. Soy: Usefulness and Safety (last updated April 2025), 2025-04. nccih.nih.gov
Sources

Sources

  1. NCCIH. Soy: Usefulness and Safety (last updated April 2025), 2025-04. nccih.nih.gov
  2. Memorial Sloan Kettering Cancer Center. About Herbs: Soy (Last Updated July 24, 2026), 2026-07-24. mskcc.org
  3. EFSA ANS Panel. Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA Journal 2015;13(10):4246 (published 21 October 2015), 2015-10-21. efsa.europa.eu
  4. Taku K, et al. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause 2012;19(7):776-90 (PMID 22433977), 2012-07. pubmed.ncbi.nlm.nih.gov
  5. Taku K, et al. Effects of extracted soy isoflavones alone on blood total and LDL cholesterol: meta-analysis of randomized controlled trials. Ther Clin Risk Manag 2008;4(5):1097-103 (PMID 19209289), 2008-10. pubmed.ncbi.nlm.nih.gov
  6. Inpan R, et al. Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 2024;35(3):413-430 (PMID 37875614), 2024-03. pubmed.ncbi.nlm.nih.gov
  7. Liu J, et al. Oral isoflavone supplementation on endometrial thickness: a meta-analysis of randomized placebo-controlled trials. Oncotarget 2016;7(14) (PMID 26967050), 2016-04. pubmed.ncbi.nlm.nih.gov
  8. Setchell KD, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131(4 Suppl):1362S-75S (PMID 11285356), 2001-04. pubmed.ncbi.nlm.nih.gov
  9. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  10. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in this category: Alpha-lipoic acid · Bee pollen · Beetroot juice (dietary nitrate) · Berberine · Beta-glucan (oat and barley) · Betaine (trimethylglycine) · Bromelain · Caffeine · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.